Publications by authors named "Laura Abril"

Claim this Profile
O
Optical Genome Mapping (OGM): Validation and Clinical Utility in the Cytogenetic Diagnosis of Multiple Myeloma.
Adela Cisneros, Mar Mallo, Aleix Méndez-López, Carmen Villena, Encarnación Santafé, Laura Abril

Am J Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain.
Carlos Fernández de Larrea, Javier Loscertales, Valentín Cabañas, Carmen Freiria, María Jesús Blanchard, Laura Abril

Ther Adv Hematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin for the treatment of multiple myeloma.
Albert Oriol, Gladys Ibarra, Jordi Loscos, Laura Abril

Expert Opin Biol Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line treatment of multiple myeloma in both transplant and non-transplant candidates.
Albert Oriol, Laura Abril, Gladys Ibarra

Expert Rev Anticancer Ther· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era.
Julio Del Río-Garma, Sabela Bobillo, Javier de la Rubia, Cristina Pascual, Faustino García-Candel, Laura Abril

Ann Hematol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myeloma.
Gladys Ibarra, Marta Peña, Laura Abril, Alicia Senín, Clara Maluquer

Eur J Haematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma.
Albert Oriol, Laura Abril, Anna Torrent, Gladys Ibarra, Josep-Maria Ribera

Ther Adv Hematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited treatment options in refractory multiple myeloma: promising therapeutic developments.
Albert Oriol, Laura Abril, Gladys Ibarra, Alicia Senin

Expert Rev Anticancer Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?
Susanna Gassiot, Yolanda González, Mireia Morgades, Cristina Motlló, Victòria Clapés, Laura Abril

Clin Lymphoma Myeloma Leuk· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis